Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
02/13/24, 1:03 PM
Location
menlo parkMoney raised
$147 million
Industry
biotechnology research
Round Type
series b
Investors
Velosity Capital, Eventide Asset Management, Monograph Capital, Surveyor Capital, Frazier Life Sciences, Sanofi Ventures, The Rise Fund, Tpg Life Sciences Innovations, Enavate Sciences, Upmc Enterprises, Leaps By Bayer, Sv Health Investors Fund, Dementia Discovery Fund (Ddf)
Sudo Biosciences announced the second close of its upsized Series B financing, bringing the total raised in the round to $147M. The funding will be used to advance two investigational TYK2 candidates into the clinic this year, including a potential first and best-in-class brain-penetrant TYK2 therapeutic for multiple sclerosis, Alzheimer’s Disease, and ALS, as well as a potential first and best-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.
Company Info
Location
menlo park, california, united states
Additional Info
Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.